The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Nazli Dizman
Stock and Other Ownership Interests - Several pharmaceutical companies (I)
Consulting or Advisory Role - Eisai
 
Sahil Doshi
Honoraria - BioMedical Insights; IntrinsiQ
 
Antonio Ocejo
No Relationships to Disclose
 
Andrea Knezevic
Consulting or Advisory Role - ByHeart
 
Maria Julia Moura Nascimento Santos
No Relationships to Disclose
 
Andrew Cornish
No Relationships to Disclose
 
Amado Zurita
Consulting or Advisory Role - Bayer; Dendreon; Exelixis; Hikma Pharmaceuticals; Janssen Oncology; Pfizer/Astellas
Speakers' Bureau - CancerNet; Hikma Pharmaceuticals; Janssen Oncology; McKesson
Research Funding - ABX Advanced biochemical compounds; Clarity Pharmaceuticals; Fusion Pharmaceuticals; Merck; Pfizer/Astellas
 
Matthew Campbell
Honoraria - Curio Science; Eisai; Eisai; Exelixis; Merck; MJH Life Sciences; OnViv; Pfizer; Targeted Oncology
Research Funding - Exelixis (Inst); Genentech (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - Exelixis; SeaGen
 
Ritesh Kotecha
Consulting or Advisory Role - Eisai; Eisai; Guidepoint Inc; Guidepoint Inc
Research Funding - Allogene Therapeutics (Inst); ArsenalBio (Inst); Exelixis (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst); Xencor (Inst)
 
Eric Jonasch
Consulting or Advisory Role - Arcus Biosciences; Aveo; Eisai; Exelixis; GlaxoSmithKline; Ipsen; Merck; NiKang Therapeutics; Novartis; Takeda; Telix Pharmaceuticals
Research Funding - Abbvie (Inst); Aveo (Inst); Bristol Myers Squibb Foundation (Inst); Corvus Pharmaceuticals (Inst); Merck (Inst); NiKang Therapeutics (Inst); ProfoundBio (Inst); Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Neil Shah
Honoraria - MJH Life Sciences
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Merck Sharp & Dohme Corp.
Research Funding - Aravive (Inst); Exelixis (Inst); HiberCell (Inst)
Travel, Accommodations, Expenses - Merck
 
Omar Alhalabi
Consulting or Advisory Role - Adaptimmune; AstraZeneca; Bicycle Therapeutics; Cardinal Health; Seagen; Silverback Therapeutics
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Genentech (Inst); Ikena Oncology (Inst)
 
Marie Carlo
Honoraria - OncLive/MJH Life Sciences; OncLive/MJH Life Sciences
Other Relationship - Kidney Cancer Association; Prostate Cancer Foundation; Robert Wood Johnson Foundation
 
Amishi Shah
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Exelixis; Pfizer/EMD Serono
Research Funding - 4D Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); EMD Serono (Inst)
 
Darren Feldman
Consulting or Advisory Role - BioNTech; Debiopharm Group; Exelixis; Novo Nordisk (I); Shabas; Telix Pharmaceuticals; Xencor
Speakers' Bureau - Novo Nordisk (I)
Research Funding - Bristol-Myers Squibb/Roche; Exelixis; GlaxoSmithKline (I); Lilly (I); Merck (I); Telix Pharmaceuticals
Other Relationship - UpToDate
 
Pavlos Msaouel
Honoraria - Exelixis; Mirati Therapeutics; Pfizer
Consulting or Advisory Role - Axiom Healthcare Strategies
Research Funding - Bristol-Myers Squibb (Inst); Gateway for Cancer Research (Inst); Mirati Therapeutics (Inst); Summit Therapeutics; Takeda (Inst)
 
Robert Motzer
Consulting or Advisory Role - Merck
Research Funding - Aveo (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Merck (Inst); Pfizer (Inst)
 
Nizar Tannir
Stock and Other Ownership Interests - Amgen; BioCryst; Johnson & Johnson/Janssen; Spdr S&P Pharmaceuticals ETF; Surface Oncology; Vanguard Health Care
Honoraria - Bristol-Myers Squibb; Eisai; Intellisphere; Ipsen; Merck Sharp & Dohme; Oncorena
Research Funding - Arrowhead Pharmaceuticals Inc. (Inst); Bristol Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Nektar (Inst); Novartis (Inst)
 
Martin Voss
Consulting or Advisory Role - Affimed Therapeutics; AstraZeneca; AVEO; Eisai; Exelixis; Merck; Oncorena
Research Funding - Exelixis; Pfizer; Regeneron
(OPTIONAL) Uncompensated Relationships - Aravive; AstraZeneca; BMS; Genentech/Roche; NiKang Therapeutics
 
Andrew Hahn
Honoraria - Binacea; Curio Science; Dava Oncology; IDEOlogy Health; Kaplan Partners in Knowledge; Mashup Media; Medscape; MJH Life Sciences
Consulting or Advisory Role - AVEO; Eisai; Exelixis; Intellisphere; Janssen Scientific Affairs; Pfizer; Tolmar
Research Funding - Bayer; Bristol Myers Squibb; Eisai (Inst); Halda Therapeutics
Travel, Accommodations, Expenses - Dava Oncology